

A Multicenter, Prospective, Observational Study to Determine Association of Mesangial C1q Deposition with Renal Outcomes in IgA Nephropathy

Li Tan, MD ^{1,5,6}, Yi Tang, MD ¹, Gaiqin Pei, MD ^{1,6}, Zhengxia Zhong, MD ^{2,6}, Jiaying Tan, MD ^{1,6}, Ling Zhou, MD ^{3,6}, Dongmei Wen, MD ^{4,6}, David Sheikh-Hamad, MD ⁵, Wei Qin, MD ¹

¹ Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

² Division of Nephrology, Department of Medicine, Affiliated Hospital of Zunyi Medical University, Medical University, Zunyi, Guizhou, China.

³ Division of Nephrology, Zigong Third People's Hospital, Zigong, Sichuan, China.

⁴ Division of Nephrology, People's Hospital of Jianyang, Chengdu, Sichuan, China.

⁵ Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

⁶ West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.

Correspondence to: Wei Qin, Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Tel. 86-28-85422338, Fax +86-028-8542-3341. Email qinweihx@scu.edu.cn.

TableS3. Clinical outcome of IgAN patients.

	CR	PR	NR	ESRD/ Death
Before PS matching (n=1071)				
C1-positive (n=145)	76 (52.4%)	14 (9.7%)	32 (22.1%)	23 (15.9%)
C1-negative (n=926)	589 (63.6%)	102 (11.0%)	133 (14.4%)	102 (11.0%)
After 1:1 PS matching (n=290)				
C1-positive (n=145)	76 (52.4%)	14 (9.7%)	32 (22.1%)	23 (15.9%)
C1-negative (n=145)	101 (69.7%)	18(12.4%)	17 (11.7%)	9 (6.2%)

Note: Values for categorical variables are given as number (percentage). Abbreviations: CR, complete remission; PR, partial remission; NR, no response; ESRD, end stage renal disease.